Dermata Therapeutics (NASDAQ:DRMA – Get Free Report) and Niagen Bioscience (NASDAQ:NAGE – Get Free Report) are both small-cap consumer staples companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, dividends, valuation, earnings, profitability and analyst recommendations.
Insider and Institutional Ownership
8.7% of Dermata Therapeutics shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 21.9% of Dermata Therapeutics shares are held by insiders. Comparatively, 10.0% of Niagen Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Dermata Therapeutics and Niagen Bioscience”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dermata Therapeutics | N/A | N/A | -$7.56 million | ($4.39) | -0.30 |
| Niagen Bioscience | $129.42 million | 1.93 | $17.38 million | $0.18 | 17.39 |
Niagen Bioscience has higher revenue and earnings than Dermata Therapeutics. Dermata Therapeutics is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Dermata Therapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Comparatively, Niagen Bioscience has a beta of 2.09, meaning that its share price is 109% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings for Dermata Therapeutics and Niagen Bioscience, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dermata Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Niagen Bioscience | 0 | 1 | 3 | 1 | 3.00 |
Niagen Bioscience has a consensus price target of $10.33, suggesting a potential upside of 230.14%. Given Niagen Bioscience’s stronger consensus rating and higher probable upside, analysts plainly believe Niagen Bioscience is more favorable than Dermata Therapeutics.
Profitability
This table compares Dermata Therapeutics and Niagen Bioscience’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Dermata Therapeutics | N/A | -166.66% | -130.13% |
| Niagen Bioscience | 12.39% | 17.95% | 13.17% |
Summary
Niagen Bioscience beats Dermata Therapeutics on 13 of the 14 factors compared between the two stocks.
About Dermata Therapeutics
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
About Niagen Bioscience
Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.
Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
